Introduction
Recent advances in chemotherapies, hormonal therapies and anti-human epidermal growth factor receptor 2 (HER2) therapies have significantly improved the prognosis in metastatic recurrent breast cancer patients. For example, new chemotherapies using agents such as nanoparticle albumin-bound paclitaxel (nab-PTX) [
1,
2], eribulin mesylate [
3,
4] and bevacizumab [
5‐
7], new hormonal therapies such as fluvestrant injection [
8,
9] or new anti-HER2 therapies such as those using pertuzumab [
10,
11] and trastuzumab emtansine (T-DM1) [
12] have shown significant clinical benefits in metastatic recurrent breast cancer patients. Despite these novel therapeutic advances, the treatment modalities for chemotherapy-resistant triple-negative breast cancer (TNBC) remain limited, and thus a novel treatment approach including immunotherapy is required. Nevertheless, no randomized controlled trials of cancer vaccine have shown promise of clinical benefit for metastatic recurrent breast cancer patients, particularly in metastatic recurrent TNBC (mrTNBC).
We have developed a novel regimen of personalized peptide vaccination (PPV), in which vaccine antigens are selected from a pool of 31 different peptide candidates based on the pre-existing immunoglobulin G (IgG) responses specific to each peptide before vaccination [
13‐
17]. Most of the peptides employed for PPV, except for those derived from prostate-related antigens, are known to be commonly expressed in various types of advanced cancers. Our previous clinical trials of PPV for patients with advanced cancers demonstrated the safety and feasibility of this new approach [
13‐
17]. Here we conducted a phase II study of PPV for metastatic recurrent breast cancer to investigate the feasibility of PPV for mrTNBC.
Methods
Patients and methods
Women with a histological diagnosis of metastatic recurrent breast cancer were eligible for inclusion in the present study. All patients were required to have evaluable recurrent and/or metastatic tumors at the time of entry. Patients were divided into three different intrinsic subtypes as follows: luminal (estrogen-receptor-positive)/HER2-negative type, HER2-positive type (immunohistochemical score 3+ or HER2 gene/chromosome 17 ratio >2.2 in fluorescence
in situ hybridization) and TNBC (hormone-receptor-negative and HER2-negative). Most patients had failed standard chemotherapy, but a few patients who had failed hormonal therapy alone were also eligible for this study. All patients were required to show positive IgG responses to at least 2 of the 31 different vaccine candidate peptides, as reported previously [
13‐
17]. Other inclusion criteria were as follows: age between 20 and 80 years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; positive status for human leukocyte antigen (HLA)-A2, -A24 or -A26 types, or HLA-A3 supertypes (A3, A11, A31 or A33); life expectancy of at least 12 weeks; and adequate hematologic, hepatic and renal function. Exclusion criteria included pulmonary, cardiac or other systemic diseases; an acute infection; a history of severe allergic reactions; pregnancy or nursing; and other inappropriate conditions for enrollment as judged by clinicians. Patients with a lymphocyte count of <1,000/μL were excluded from the study, since we previously reported that pre-vaccination lymphocytopenia (<1,000 cells/μL) is an unfavorable factor for overall survival (OS) in cancer patients receiving PPV [
17]. The protocol was approved by the Kurume University Ethical Committee and registered in the UMIN Clinical Trials Registry (Registration, number UMIN000001844; Registration date, 5 April 2009). All patients were given a full explanation of the protocol and provided their informed consent before enrollment.
Clinical protocol
This was a phase II study to evaluate the safety and immunological responses in metastatic recurrent breast cancer patients under PPV. Thirty-one peptides, whose safety and immunological effects for other types of cancer were confirmed in previously conducted clinical studies [
14‐
17], were employed for vaccination (12 peptides for HLA-A2, 16 peptides for HLA-A24, 9 peptides for HLA-A3 supertypes (-A3, -A11, -A31, and -A33) and 4 peptides for HLA-A26) (Additional file
1: Table S1). These peptides were prepared under the conditions of Good Manufacturing Practice (GMP) by the PolyPeptide Laboratories (San Diego, CA, USA) and American Peptide Company (Vista, CA, USA). Peptides for vaccination of individual patients were selected in consideration of the pre-existing host immunity before vaccination, as assessed by the titers of IgG specific to each of the 31 different vaccine candidates.
A maximum of four peptides (3 mg/each peptide), which were selected based on the results of HLA typing and peptide-specific IgG titers, were subcutaneously administered with incomplete Freund’s adjuvant (Montanide ISA51; Seppic, Paris, France) once a week for six consecutive weeks. After the first cycle of six vaccinations, up to four antigen peptides, which were re-selected according to the titers of peptide-specific IgG at the sixth vaccination, were administered every two weeks. After the second cycle of six vaccinations, up to four antigen peptides, which were also re-selected, were administered every four to eight weeks according to the immune responses after PPV. These protocols were continued until remarkable disease progression or disease in remission was shown, according to the will of the individual patient. During the PPV, patients were allowed to receive combination therapies such as chemotherapy, hormonal therapy, anti-HER2 therapy and radiotherapy. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTC Ver.-3.0). Complete blood counts and serum biochemistry tests were performed after every six vaccinations. The clinical responses were determined by the Response Evaluation Criteria in Solid Tumors (RECIST) in the vaccinated patients. The RECIST-based clinical responses were evaluated after nearly 12 vaccinations by radiological findings of computed tomography (CT) scan and/or magnetic resonance imaging (MRI), and the best overall responses during PPV treatment were shown. For the patients who did not complete the second cycle of 12 vaccinations, the newest radiological findings were evaluated, except in the case of patients who had died before the RECIST-based radiological evaluation.
Measurement of humoral and cellular immune responses
Humoral immune responses specific to each of the 31 peptide candidates were determined by peptide-specific IgG levels using the Luminex system (Luminex, Austin, TX, USA), as previously reported [
18]. If the titers of peptide-specific IgG to at least one of the vaccinated peptides in the post-vaccination plasma were more than two-fold higher than those in the pre-vaccination plasma, the changes were considered to be significant, as previously reported [
14‐
17]. Cellular immune responses specific to the vaccinated peptides were evaluated by interferon (INF)-γ ELISPOT using peripheral blood mononuclear cells (PBMCs) as previously reported [
14‐
17]. As a control, cellular immune responses specific to CEF peptides (MABTECH, Cincinnati, OH, USA), a mixture of virus-derived cytotoxic T lymphocyte (CTL) epitopes, were also examined.
Statistical analyses
The Mann-Whitney U test and Fisher-Freeman-Halton exact test were used to examine statistical differences for continuous values and categorical values, respectively. P-values less than 0.05 were considered to be statistically significant. Progression-free survival (PFS) or OS was calculated from the date of the first vaccination until the date of disease progression or death, respectively, or the last date when the patient was known to be alive. The survival analysis was performed using the Kaplan-Meier method, and a comparison of the survival curves was performed with the log-rank test. Statistical tests were performed using JMP version 10 (SAS Institute Inc., Cary, NC, USA) and StatXact version 8 (Cytel Inc., Cambridge, MA, USA).
Discussion
Since treatment outcomes in mrTNBC patients remain poor [
19‐
21], a novel treatment modality including immunotherapy is required. Several tumor associated antigens (TAAs), such as cancer testis antigens, EGF-R, aldehyde dehydrogenase 1 (ALDH1) and enhancer of zeste homolog 2 (EZH2), are frequently expressed in TNBC, particularly in basal-like subtypes [
22‐
24]. Despite these potential molecular targets for immunotherapy in TNBC, no randomized controlled trials of cancer vaccine have shown promise of clinical benefit to date. We have developed a novel regimen of PPV, in which vaccine antigens are selected and administered from a pool of 31 different peptide candidates based on the pre-existing IgG responses specific to peptides before vaccination [
13‐
17]. In previous studies, PPV was feasible for the vast majority of cancer patients with different HLA-types [
13‐
17]. Based on these results in cancer patients, we conducted a phase II study of PPV for metastatic recurrent breast cancer patients to investigate the feasibility of PPV for mrTNBC. There were no severe adverse events associated with PPV, and most of the mrTNBC patients showed augmented immune responses to PPV.
The current study suggested the feasibility of PPV for mrTNBC patients who had failed standard chemotherapy, since the MPFST and MST of mrTNBC patients were 7.5 and 11.1 months from the first vaccination, respectively. In previously reported studies, the MPFST of mrTNBC patients treated by various chemotherapy and/or targeted therapy regimens was between 2.5 and 6.5 months [
7,
25‐
28]. Therefore, the MPFST of 7.5 months in mrTNBC patients treated by PPV in the current study seemed to be promising. Regarding OS in TNBC patients, Dent
et al. demonstrated that the MST from recurrence to death was nine months, although the details of chemotherapy regimens were not described [
19]. More recently conducted studies showed that the MST of mrTNBC patients treated by various chemotherapy and/or targeted therapy regimens was between 7.7 and 17.9 months [
26‐
28]. Although almost all patients in these previous studies were enrolled as a first-line and/or second-line treatment [
26‐
28], most patients in the current study were enrolled as a third or more line treatment. In addition, considering that the median duration of previous chemotherapies in the mrTNBC patients in the current study was 9 months, the MST of 11.1 months in mrTNBC patients treated by PPV seems to be encouraging. As a next step, to clarify the clinical benefit of PPV in mrTNBC, we need to conduct a randomized controlled study, in which patients are treated with standard of care (SOC) alone or with PPV plus SOC.
Although the results of immune responses were not significantly different by intrinsic subtypes, a high population of HER2-positive patients showed IgG responses at the sixth vaccination. Since all of the HER2-positive patients had been treated with trastuzumab, antigen-dependent cellular cytotoxicity might have affected their humoral immunities [
29]. Notably, IgG boosting was a significant prognostic factor for OS and PFS in HER2-positive patients, although the number of patients was too small to confirm this. Combined chemotherapies also might affect the status of IgG responses, but no survival advantages of combined chemotherapies were shown in our metastatic recurrent breast cancer patients.
The clinical response rate in the present series was 14.0%, including three CR and six PR cases. Among these responsive patients, combined chemotherapy was used in eight cases and hormonal therapy in one case. The intrinsic subtype of these patients was luminal/HER2-negative type in seven cases and mrTNBC in two cases. Notably, the number of previous chemotherapy regimens was one regimen in two patients and two regimens in seven patients. In our study, more than four regimens of previous chemotherapy were significantly correlated with poor prognosis (data not shown). From these results, we would recommend PPV within three regimens of previous chemotherapy for metastatic recurrent breast cancer patients. A greater number of previous chemotherapy regimens could not sufficiently enhance clinical responses to PPV, particularly in HER2-positive patients. Because of the significant clinical benefit and conventional usage of trastuzumab, the duration of previous chemotherapy was significantly prolonged in HER2-positive patients. The status of tumor molecular biology could change and be complicated by this long-term chemotherapy, eventually leading to a poor prognosis. For HER2-positive patients, the induction of PPV should be earlier than that in our HER2-positive patients. Since combined chemotherapies increase the number of severe adverse events in metastatic breast cancer patients, treatment with PPV alone should be performed to maintain their quality of life.
We had an opportunity to confirm the peritumoral infiltration of lymphocytes in the lung metastasis of mrTNBC. Two of the four vaccinated peptide antigens (EGF-R and squamous cell carcinoma antigen recognized by T-cells 2 (SART2)) were expressed in the lung tumor, and CTL responses to the SART2-93 antigen were significantly increased in this case (case 18 in Additional file
2: Table S2). Although IgG responses to the two peptide antigens were not significantly increased, PPV could enhance the anti-tumor immunity and efficacy of combined chemotherapy in this case. We have investigated the expressions of 15 TAAs in primary and recurrent breast cancer tissues by immunohistochemistry (RT, unpublished data). We found that 10 of 15 TAAs were expressed in both primary and recurrent breast cancer tissues, except for lymphocyte specific protein tyrosine kinase (LCK), prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) and multidrug resistance-associated protein 3 (MRP3). However, four of these five TAAs, including LCK, PSA, PAP and MRP3, were reported to be expressed in breast cancer tissues, although the frequency of expression was lower than that of other TAAs [
30‐
34]. Therefore, 14 of the 15 TAAs could be potential molecular targets for immunotherapy in breast cancer patients.
Competing interests
Akira Yamada, is a Board member of the Green Peptide Company, Ltd. Kyogo Itoh and Akira Yamada have stock of the Green Peptide Company, Ltd. Kyogo Itoh received research fund from Taiho Pharmaceutical Company. The other authors declare that they have no competing interests.
Authors’ contributions
RT, UT and KI are responsible for the conception and design of the study, the acquisition, analysis and interpretation of data, and drafting the work. TS is responsible for the interpretation of data and drafting the work. NI, MT, HO, MF, TF, NS, YA and AY are responsible for the interpretation of data and revising the work critically. AK, MK and SM are responsible for the acquisition and analysis of data and revising the work critically. All authors read and approved the final manuscript.